BIO Comment on Executive Order 13777, Enforcing the Regulatory Reform Agenda
May 15, 2017
The Biotechnology Innovation Organization’s (“BIO”) Industrial and Environmental Section (“IES”) is pleased to provide the U.S. Environmental Protection Agency (“EPA”) input to inform its Task Force evaluation of existing regulations under Executive Order 13777, “Enforcing the Regulatory Reform Agenda.”
Download Full Comments Below
BIO Comments - Docket ID No. EPA-HQ-OA-2017-0190 - EO 13777 Enforcing The Regulatory Reform Agenda
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.
The Biotechnology Innovation Organization’s (“BIO”) Industrial and Environmental Section (“IES”) is pleased to provide the U.S. Environmental Protection Agency (“EPA”) input to inform its Task Force evaluation of existing regulations under Executive Order 13777, “Enforcing the Regulatory Reform Agenda.”